mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR+/HER2− breast cancer
Open Access
- 19 February 2026
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Abstract
Breast cancer (BC) is the most prevalent malignancy in women, with hormone receptor-positive, HER2-negative (HR + /HER2 − ) tumors representing ~70% of cases. While CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have transformed treatment for metastatic HR + /HER2 − BC, acquired resistance remains a major obstacle. Using HR + /HER2 − BC models with acquired resistance to the CDK4/6 inhibitors Palbociclib or Ribociclib, we uncovered a metabolic vulnerability in highly resistant clones, mediated by mTORC1 hyperactivation and autophagy suppression. Gene expression profiling revealed enrichment of glycolysis and mTORC1 pathways in CDK4/6i-resistant cells, which manifested as heightened sensitivity to the metabolic inhibitors Metformin and Dichloroacetate (DCA). Mechanistically, mTORC1 overactivation impaired autophagy via ULK1-Ser757 phosphorylation, as confirmed by LC3 flux assays, leaving resistant cells unable to adapt to energy stress. Treatment with metabolic drugs triggered AMPK activation, ACC inhibition, and PARP cleavage, culminating in apoptosis. Clinically, immunohistochemical analysis of a BC cohort revealed a significant correlation between mTORC1 activity (p4E-BP1 T37/46 ) and autophagy suppression (p62 accumulation), supporting the translational relevance of this axis. Our findings propose mTORC1-mediated autophagy defects as a biomarker for metabolic vulnerability in CDK4/6i-resistant BC, offering a rationale for targeting these tumors with metabolic therapies to overcome resistance.Keywords
This publication has 61 references indexed in Scilit:
- Changes in the incidence of early-onset breast cancer in Germany between 2010 and 2022Breast Cancer Research and Treatment, 2023
- Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitorsScience China Life Sciences, 2022
- Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1Cell Reports, 2020
- Mechanisms of Sensitivity and Resistance to CDK4/6 InhibitionCancer Cell, 2020
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A reviewInternational Journal of Cancer, 2018
- Autophagy and Tumor MetabolismCell Metabolism, 2017
- mTOR Signaling in Growth, Metabolism, and DiseaseCell, 2017
- The Emerging Hallmarks of Cancer MetabolismCell Metabolism, 2016
- Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated With Estrogen Receptor-Negative Subtypes and Poor PrognosisEBioMedicine, 2015
- Autophagy: Renovation of Cells and TissuesCell, 2011